» Articles » PMID: 24142430

Prevention of VEGF-mediated Microvascular Permeability by C-peptide in Diabetic Mice

Overview
Journal Cardiovasc Res
Date 2013 Oct 22
PMID 24142430
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Human C-peptide has a beneficial effect on the prevention of diabetic neuropathy, nephropathy, and vascular complications; however, its role in protection against increased vascular permeability in diabetes remains unclear. Our purpose was to explore the potential protective role of C-peptide against microvascular permeability mediated by vascular endothelial growth factor (VEGF)-induced reactive oxygen species (ROS) generation in diabetes.

Methods And Results: Generation of intracellular ROS, real-time changes in intracellular Ca(2+), ROS-dependent stress fibre formation, and the disassembly of the adherens junctions were studied by a confocal microscopy in human umbilical vein endothelial cells (HUVECs). VEGF-induced vascular leakage was investigated in the skin of diabetic mice using a Miles vascular permeability assay. Microvascular leakage in the retina of streptozotocin diabetic mice was investigated using a confocal microscopy after left ventricle injection of fluorescein isothiocyanate (FITC)-dextran. C-peptide inhibited the VEGF-induced ROS generation, stress fibre formation, disassembly of vascular endothelial cadherin, and endothelial permeability in HUVECs. Intradermal injection of C-peptide prevented VEGF-induced vascular leakage. Consistent with this, intravitreal injection of C-peptide prevented the extravasation of FITC-dextran in the retinas of diabetic mice, which was also prevented by anti-VEGF antibody and ROS scavengers in diabetic mice. Conclusions/interpretation C-peptide prevents VEGF-induced microvascular permeability by inhibiting ROS-mediated intracellular events in diabetic mice, suggesting that C-peptide replacement is a promising therapeutic strategy to prevent diabetic retinopathy.

Citing Articles

GDF15 propeptide promotes bone metastasis of castration-resistant prostate cancer by augmenting the bone microenvironment.

Yamamichi G, Kato T, Arakawa N, Ino Y, Ujike T, Nakano K Biomark Res. 2024; 12(1):147.

PMID: 39587633 PMC: 11590406. DOI: 10.1186/s40364-024-00695-6.


Transglutaminase 2 in diabetes mellitus: Unraveling its multifaceted role and therapeutic implications for vascular complications.

Ha K Theranostics. 2024; 14(6):2329-2344.

PMID: 38646650 PMC: 11024853. DOI: 10.7150/thno.95742.


The role of C-peptide in diabetes and its complications: an updated review.

Chen J, Huang Y, Liu C, Chi J, Wang Y, Xu L Front Endocrinol (Lausanne). 2023; 14:1256093.

PMID: 37745697 PMC: 10512826. DOI: 10.3389/fendo.2023.1256093.


Therapeutic effect of ultra-long-lasting human C-peptide delivery against hyperglycemia-induced neovascularization in diabetic retinopathy.

Moon C, Lee A, Jeon H, Kim E, Ha K Theranostics. 2023; 13(8):2424-2438.

PMID: 37215567 PMC: 10196831. DOI: 10.7150/thno.81714.


Association between lipocalin-2 levels and diabetic retinopathy in patients with overweight/obese type 2 diabetes mellitus.

Zhang Y, Song X, Qi T, Gao S, Sun C, Yang J Ir J Med Sci. 2023; 192(6):2785-2792.

PMID: 37069380 DOI: 10.1007/s11845-023-03365-y.